Products.

Done Right.

Shifamed has a history of entrepreneurial success founding cutting edge medical technology companies and bringing highly-valued products to market, either direct or through an acquisition.

We have the experience, knowledge, and a demonstrated ability to discern new technologies that represent compelling business opportunities and structure deals, which provide a rapid return for our investors.

Currently, Shifamed is busy working on several companies that range in development phase from stealth mode and early stage design to commercial release and next generation work. For more information on our portfolio companies, see below or contact them directly.

Current Portfolio Companies

Apama Medical focuses on the development of an innovative approach to the treatment of atrial fibrillation (AF).

Atia Vision focuses on the development of an accommodating intraocular lens for the ophthalmology market.

NuVera Medical is focused on developing a novel imaging platform for use in a growing number of complex cardiovascular procedures.

Supira Medical is in stealth mode.

Kalila Medical, a company that provides catheters to address the myriad of delivery and access challenges seen in complex electrophysiology procedures and vascular interventions, was sold to Abbott in 2016.

Maya Medical, a renal denervation company, was sold in 2012 to Covidien for $230M.

Sadra Medical, a percutaneous aortic valve replacement company, was sold in 2011 to Boston Scientific for $450M.

Embolic Protection, Inc. (EPI), an intravascular filter company, was sold to Boston Scientific in 2001.

Products.

Done Right.

Shifamed has a history of entrepreneurial success founding cutting edge medical technology companies and bringing highly-valued products to market, either direct or through an acquisition.

Current Portfolio Companies

Legacy Portfolio Companies